AIG1 Inhibitors
Chemical inhibitors of AIG1 can impact its activity through various mechanisms, primarily by disrupting the signaling pathways and cellular processes it is involved in. Staurosporine, as a broad-spectrum protein kinase inhibitor, can impede the phosphorylation events necessary for AIG1's activity, thereby leading to its functional inhibition. Similarly, LY294002 and Wortmannin, both phosphoinositide 3-kinase (PI3K) inhibitors, can disrupt the PI3K signaling cascade. This disruption can cause a decrease in downstream signaling events that AIG1 may rely upon for its activity within the cell. U0126 and PD98059, both inhibitors of MEK, target the MAPK/ERK pathway; this inhibition leads to a reduction in ERK activation, which is a pathway that can be crucial for the functional role of AIG1. SB203580 focuses on inhibiting p38 MAPK, affecting the stress response pathways that are another potential aspect of AIG1's role in cellular responses.
In addition to these, PF-4708671 and Rapamycin target components of the mTOR pathway, with PF-4708671 specifically inhibiting p70S6 Kinase and Rapamycin targeting mTOR itself. The inhibition of these kinases can lead to a decrease in cellular growth and proliferation signals, which AIG1 is suggested to be associated with. SP600125, a c-Jun N-terminal kinase (JNK) inhibitor, can alter the stress and inflammation response, potentially affecting AIG1's function in these processes. On the other hand, proteasome inhibitors such as MG132 and Bortezomib can induce the accumulation of proteins within the cell, which can indirectly affect AIG1's function by disrupting the protein turnover processes that are essential for its regular activity. Lastly, Lestaurtinib, a tyrosine kinase inhibitor, impedes various tyrosine kinase-related signaling pathways, which AIG1 may depend on for its proper function within the cell. The collective action of these inhibitors can lead to a broad inhibition of AIG1's function by affecting the phosphorylation, signaling pathways, and protein turnover processes it is involved in.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a potent inhibitor of protein kinases. AIG1 is known to have ATPase activity, and by inhibiting kinases, Staurosporine can reduce the phosphorylation necessary for AIG1's activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. Since PI3K signaling is involved in many cellular processes including those related to AIG1's functions, inhibition of PI3K can decrease AIG1's activity by reducing downstream signaling. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK, which is upstream in the MAPK/ERK pathway. AIG1 is implicated in stress responses, and inhibition of MEK can lead to reduced ERK activation, thereby inhibiting AIG1's associated responses. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. By inhibiting p38 MAPK, SB203580 can disrupt stress response pathways in which AIG1 is involved, leading to its functional inhibition. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG132 is a proteasome inhibitor. The ubiquitin-proteasome pathway is crucial for protein turnover, and by inhibiting this pathway, MG132 can lead to an accumulation of proteins that may inhibit AIG1's function indirectly. | ||||||
PF 4708671 | 1255517-76-0 | sc-361288 sc-361288A | 10 mg 50 mg | $179.00 $700.00 | 9 | |
PF-4708671 is a specific inhibitor of the p70S6 Kinase. This kinase is part of the mTOR pathway, which is associated with cellular growth and proliferation processes that AIG1 may be part of. Inhibition of p70S6 Kinase can lead to reduced AIG1 activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK). By inhibiting JNK, SP600125 can alter the cellular response to stress and inflammation, processes in which AIG1 may play a role, thus inhibiting its function. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases. By inhibiting these kinases, it can disrupt signaling pathways that are necessary for AIG1's functional role in the cell, leading to inhibition. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an inhibitor of MEK, which functions upstream of ERK in the MAPK pathway. Inhibiting MEK leads to decreased ERK pathway activity, thereby inhibiting processes in which AIG1 is involved. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor. Since AIG1 is implicated in cellular growth processes that could be regulated by the mTOR pathway, inhibition of mTOR by Rapamycin can lead to AIG1 inhibition. | ||||||